Methotrexate 1gm/10mL
| Product Overview | |
| Generic Name | Methotrexate 1gm/10mL |
| Brand Name(s) | Rheumatrex, Trexall |
| Form | Injectable, multidose vial |
| Strength | 1 gm/10 mL 25mg/mL |
| Therapeutic Class | Antimetabolite; folic acid analogue with immunosuppressant & antineoplastic activity |
| ATC Code | L04AX03 |
| Manufacturing & Regulatory | |
| Manufacturer | Actavis, Teva |
| Country | India |
| GMP Compliance | WHO-GMP certified |
| DMF/CEP | Type II |
| COFEPRIS | Batch-specific |
| Free Sale Certificate | Yes |
| Logistics & Export | |
| MOQ | 100 units |
| Shelf Life | 36 months |
| Storage | 2–8 °C, protect from light |
| Incoterms | Ex-Works Mexico |
| Lead Time | 7 to 10 Days |
| Documentation | |
| Certificate of Analysis (COA) | Yes |
| SDS | Upon Request |
| CTD Summary | Upon Request |
Description
Presentation: 1 g/vial (25 mg/mL when reconstituted) Powder for Reconstitution. Indications and Usage – Methotrexate is indicated for the treatment of certain cancers, including breast cancer, lung cancer, head and neck cancers, and advanced-stage trophoblastic neoplasms. It is also used in high-dose regimens for osteosarcoma and as part of combination chemotherapy protocols.
